[artículo] 
inEuropean Neuropsychopharmacology > Año 2014 - Vol. 24 - No.7 (Julio) . - pp. 1024-1036

Título :	A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia -- Results from the CandleLyte study
Tipo de documento:	texto impreso
Autores:	Dragana Bugarski Kirola, Autor ; Alice Wang, Autor ; Danielle Abi Saab, Autor
Fecha de publicación:	2021
Artículo en la página:	pp. 1024-1036
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Etiquetas:	Esquizofrenia, Inhibidor de la recaptación de glicina, Bitopertina, Monoterapia, Exacerbación aguda, Receptor de NMDA
Resumen:	Bitopertin is a glycine reuptake inhibitor postulated to improve N-methyl-d-aspartate receptor hypofunction by increasing synaptic glycine concentrations. This randomised, double-blind, placebo- and active-controlled phase II/III trial evaluated the efficacy and safety of bitopertin monotherapy over 4 weeks in patients with acute exacerbation of schizophrenia.
Link:	./index.php?lvl=notice_display&id=27018

[artículo] A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia -- Results from the CandleLyte study [texto impreso] / Dragana Bugarski Kirola, Autor ; Alice Wang, Autor ; Danielle Abi Saab, Autor . - 2021 . - pp. 1024-1036.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2014 - Vol. 24 - No.7 (Julio) . - pp. 1024-1036

Etiquetas:	Esquizofrenia, Inhibidor de la recaptación de glicina, Bitopertina, Monoterapia, Exacerbación aguda, Receptor de NMDA
Resumen:	Bitopertin is a glycine reuptake inhibitor postulated to improve N-methyl-d-aspartate receptor hypofunction by increasing synaptic glycine concentrations. This randomised, double-blind, placebo- and active-controlled phase II/III trial evaluated the efficacy and safety of bitopertin monotherapy over 4 weeks in patients with acute exacerbation of schizophrenia.
Link:	./index.php?lvl=notice_display&id=27018